Case 1:14-cv-01498-JBS-KMW Document 28-6 Filed 07/11/14 Page 1 of 4 PageID: 196
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit 2
`
`

`

`Case 1:14-cv-01498-JBS-KMW Document 28-6 Filed 07/11/14 Page 2 of 4 PageID: 197
`Case 1:14-cv-01498—JBS-KMW Document 28-6 Filed 07/11/14 Page 2 of 4 PagelD: 197
`
`In antares
`
`pharma
`
`ANTARES PHARMA ENTERS INTO AN EXCLUSIVE U.S. PROMOTION AND
`MARKETING AGREEMENT WITH LEO PHARMA FOR OTREXUPWI IN DERMATOLOGY
`
`LEO Pharma: A Global Leader In Dermatology And Topical Treatments For Psoriasis
`
`EWING, NJ, November 14, 2013 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced an
`exclusive promotion and marketing agreement with LEO Pharma for detailing OTREXUPTM
`(methotrexate) to dermatologists for symptomatic control of severe recalcitrant psoriasis in adults.
`Under the terms of the agreement, Antares may receive up to a total of $20 million in milestone
`payments including an upfront payment of $5 million. Antares Pharma will record all product
`revenue associated with future dermatology prescriptions and pay LEO Pharma a percentage of
`OTREXUPTM net sales generated in dermatology. LEO Pharma will be responsible for promotion and
`marketing activities in dermatology.
`
`"We are very pleased to be working with LEO Pharma on the launch of OTREXUPTM,” said Paul
`Wotton, Ph.D., President and Chief Executive Officer of Antares Pharma. “Collaborating with LEO
`on the launch creates a very strong partnership allowing Antares to team up with and benefit from a
`very successful commercial organization while LEO expands their portfolio with a new product in
`their field of expertise. With a dedicated U.S. sales force of 75 representatives focused solely on the
`treatment of psoriasis, we believe LEO Pharma will be able to introduce and establish OTREXUPTM
`as an important new treatment option with significant growth potential
`in dermatology while
`complementing our own dedicated sales representatives detailing OTREXUPTM for rheumatoid
`arthritis.”
`
`"We are excited to launch and promote OTREXUPTM to dermatologists as an important new treatment
`option for psoriasis patients and we look fonNard to working with our partner Antares to provide the
`necessary service, knowledge and expertise to successfully introduce OTREXUPTM,” said Lars
`Olsen, Executive Vice President, LEO Pharma A/S. “As a global leader in the treatment of psoriasis,
`we have continually offered innovative and novel treatment solutions to patients. The ease of use
`and improved bioavailability that OTREXUPTM delivers will expand our current portfolio of products for
`the treatment of psoriasis and help LEO Pharma continue to realize its vision of being the world’s
`leading dermatology specialty pharmaceutical company."
`
`About Psoriasis
`
`Psoriasis is a chronic autoimmune skin disease that most commonly appears as raised, red patches
`with a white build-up of dead skin cells. Psoriasis can affect the skin on any part of the body and
`occurs when the immune system sends out faulty signals that speed the growth cycle of skin cells.
`Psoriasis is generally considered to be severe if
`it covers more than 5%-10% of body surface,
`recalcitrant when it does not adequately respond to treatment and disabling when it interferes with
`basic functions such as self-care, walking, sleep, etc.
`
`lof3
`
`

`

`Case 1:14-cv-01498-JBS-KMW Document 28-6 Filed 07/11/14 Page 3 of 4 PageID: 198
`Case 1:14-cv-01498-JBS-KMW Document 28-6 Filed 07/11/14 Page 3 of 4 PagelD: 198
`
`About LEO Pharma
`
`LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than
`100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in
`1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research
`and development to delivering products and solutions to people with skin conditions. LEO Pharma is
`headquartered in Denmark and employs 4,800 people worldwide.
`For more information, visit www.leo-pharma.com.
`
`About Antares Pharma
`
`Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-
`based medicines. The Company has received marketing approval from the U.S. Food and Drug
`Administration for OTREXUPTM (methotrexate) injection for the treatment of adults with severe active
`rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with
`severe recalcitrant psoriasis. Antares Pharma is also developing VIBEX® 08 T for testosterone
`replacement therapy. The Company's technology platforms include VIBEX® disposable Medi-Jet,
`disposable multi-use pen injectors and VisionTM reusable needle-free injectors marketed as Tjet®
`and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring),
`respectively. Antares Pharma has a multi-product deal with Teva that
`includes Tev-Tropin®
`[somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX® epinephrine and
`several other products. Antares Pharma’s partnership with Ferring includes Zomacton® hGH
`(somatropin)
`injection.
`In the U.S. Antares has received FDA approval
`for Gelnique 3%T'V'
`(oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol
`gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with
`menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the
`U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing
`and marketing of the Company’s reusable needle-free injection devices and related disposables, and
`develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company’s
`corporate office and Product Development and Commercial Groups are located in Ewing, New
`Jersey.
`
`Safe Harbor Statement
`
`This press release contains fonNard-looking statements within the meaning of the safe harbor
`provisions of the Private Securities Litigation Reform Act of 1995. These statements are indicated by
`the words “may," “will,” “plans,” “intends,” “believes,” “expects,” “anticipates,” “potential,” “could,”
`“would," “should," and similar expressions. Such fonNard-looking statements are not guarantees of
`future performance and are subject to risks and uncertainties that may cause actual results to differ
`materially from those anticipated by the fonNard-looking statements. These risks and uncertainties
`include, among others, changes in revenue growth and difficulties or delays in the commercial
`launch of OTREXUPTM for rheumatoid arthritis and psoriasis, market acceptance by physicians and
`patients of new products, delays in product development and changes or delays in the regulatory
`process for existing or new product candidates. Additional information concerning these and other
`factors that may cause actual results to differ materially from those anticipated in the fonNard-looking
`statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K
`for the year ended December 31, 2012, and in the Company's other periodic reports and filings with
`the Securities and Exchange Commission. The Company cautions investors not to place undue
`reliance on the fonNard-looking statements contained in this press release. All fonNard-looking
`statements are based on information currently available to the Company on the date hereof, and the
`Company undertakes no obligation to revise or update these fonNard-looking statements to reflect
`events or circumstances after the date of this press release, except as required by law.
`
`20f3
`
`

`

`Case 1:14-cv-01498-JBS-KMW Document 28-6 Filed 07/11/14 Page 4 of 4 PageID: 199
`Case 1:14-cv-01498—JBS-KMW Document 28-6 Filed 07/11/14 Page 4 of 4 PageID: 199
`
`Investor Contacts:
`
`Jack Howarth
`Vice President, Corporate Affairs
`Antares Pharma Inc.
`
`+1 (609) 359-3016
`ihowarth@antaresgharma.com
`
`Other Contacts:
`
`Adam Estrup
`Director, Corporate Communications
`LEO Pharma A/S
`
`+45 2222 6994
`adam.estru
`leo- harma.com
`
`3of3
`
`